Product Description
Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nerre
Company Location: Europe
Company CEO:
Additional Commercial Interests: GlaxoSmithKline
Clinical Description
Countries in Clinic: Netherlands, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Cough|Idiopathic Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05185089 |
IPF-COMFORT | P2 |
Completed |
Chronic Cough|Idiopathic Pulmonary Fibrosis |
2024-06-05 |
47% |
2024-07-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2021-006278-22 |
2021-006278-22 | P2 |
Completed |
Chronic Cough|Idiopathic Pulmonary Fibrosis |
2024-06-19 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |